2023年2月第30卷第2期重组人血小板生成素联合白介素治疗白血病患儿化疗后血小板减少症的临床效果分析翟素花，刘江华（郑州大学附属儿童医院／河南省儿童医院血液肿瘤科，河南郑州450018）【摘要】目的探讨重组人血小板生成素联合白介素治疗白血病患儿化疗后血小板减少症的临床效果。方法60例白血病化疗后血小板减少症患儿随机分为两组，对照组采用白介素－11治疗，观察组采用重组人血小板生成素联合白介素－11治疗，比较两组的治疗效果、治疗指标及用药安全性。结果治疗后，观察组的总有效率高于对照组，血小板复常时间及用药治疗时间均短于对照组（P＜0．05）。两组的不良反应发生率比较，差异无统计学意义（P＞0．05）。结论重组人血小板生成素联合白介素治疗白血病患儿化疗后血小板减少症的临床效果较好，可有效缩短用药时间，且不会明显增加不良反应发生风险。【关键词】重组人血小板生成素；白介素；白血病；化疗；血小板减少症中图分类号：R733.7文献标识码：Adoi:10.3969/j.issn.1674-4659.2023.02.0203AnalysisontheClinicalEffectofRecombinantHumanThrombopoietinCombinedwithInterleukinintheTreatmentofThrombocytopeniaAfterChemotherapyinChildrenwithLeukemia//ZHAISuhua,LIUJianghua(DepartmentofHematologyandOncology,theChildren'sHospitalAffiliatedtoZhengzhouUniversity/He'nanChildren'sHospital,Zhengzhou450018,China)[Abstract]ObjectiveToexploretheclinicaleffectofrecombinanthumanthrombopoietincombinedwithinterleukininthetreatmentofthrombocytopeniaafterchemotherapyinchildrenwithleukemia.Methods60childrenwiththrombocytopeniaafterchemotherapyforleukemiawererandomlydividedintotwogroups.Thecontrolgroupwastreatedwithinterleukin-11,andtheobservationgroupwastreatedwithrecombinanthumanthrombopoietincombinedwithinterleukin-11.Thetherapeuticeffect,treatmentindicatorsandmedicationsafetywerecomparedbetweenthetwogroups.ResultsAftertreatment,thetotaleffectiverateoftheobservationgroupwashigherthanthatofthecontrolgroup,andtheplateletrecoverytimeandmedicationtimewereshorterthanthoseofthecontrolgroup(P<0.05).Nosignificantdifferencewasfoundintheincidenceofadversereactionsbetweenthetwogroups(P>0.05).ConclusionsRecombinanthumanthrombopoietincombinedwithinterleuki...
